No Data
No Data
Allarity Therapeutics Announces It Will Present Novel Drug Response Predictor For Daratumumab In Multiple Myeloma At AACR 2025 In Chicago, Illinois April 25-30, 2025
Allarity Therapeutics Restructures Board of Directors
XPeng, Ultralife And 3 Stocks To Watch Heading Into Tuesday
Allarity Therapeutics Shares Are Trading Higher After the Company Reported FY24 Financial Results and Beat Its EPS Estimate.
Allarity Therapeutics | 10-K: FY2024 Annual Report
Express News | Allarity Therapeutics FY 2025 GAAP EPS $(15.65) Beats $(46.80) Estimate